SMTL ID : 5hys.1 (1 other biounit)

Structure of IgE complexed with omalizumab

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.50 Å

Oligo State

hetero-2-2-2-mer

Ligands

2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-BMA-MAN-MAN.1: 9 residues within 4Å: Chain E: Y.15, L.35, V.37, D.38, Q.68, N.70, T.72, T.74, Q.170 2 PLIP interactions: 2 interactions with chain E Hydrogen bonds: E:Q.170, E:Q.170, E:Y.15, E:Y.15 NAG-NAG-BMA-MAN-MAN.2: 10 residues within 4Å: Chain F: P.9, Y.15, L.35, V.37, D.38, Q.68, N.70, T.72, T.74, Q.170 1 PLIP interactions: 1 interactions with chain F Hydrogen bonds: F:Q.170, F:T.74

22 x SO4: SULFATE ION(Non-functional Binders)

SO4.3: 1 residues within 4Å: Chain A: R.72 Ligand excluded by PLIP SO4.4: 5 residues within 4Å: Chain A: S.7, G.8, G.9, T.115, K.209 Ligand excluded by PLIP SO4.5: 3 residues within 4Å: Chain A: R.19, K.76, Y.80 Ligand excluded by PLIP SO4.6: 1 residues within 4Å: Chain A: K.76 Ligand excluded by PLIP SO4.7: 3 residues within 4Å: Chain B: K.43, K.46, K.49 Ligand excluded by PLIP SO4.8: 2 residues within 4Å: Chain B: S.69, G.70 Ligand excluded by PLIP SO4.9: 1 residues within 4Å: Chain B: R.24 Ligand excluded by PLIP SO4.10: 5 residues within 4Å: Chain B: S.9, S.10, K.107 Chain D: S.12, K.111 Ligand excluded by PLIP SO4.11: 5 residues within 4Å: Chain C: S.7, G.8, G.9, T.115, K.209 Ligand excluded by PLIP SO4.12: 1 residues within 4Å: Chain C: G.126 Ligand excluded by PLIP SO4.13: 3 residues within 4Å: Chain C: R.19, K.76, Y.80 Ligand excluded by PLIP SO4.14: 4 residues within 4Å: Chain D: Q.41, K.43, K.46, K.49 Ligand excluded by PLIP SO4.15: 3 residues within 4Å: Chain D: S.125, D.126, E.127 Ligand excluded by PLIP SO4.16: 5 residues within 4Å: Chain B: K.149, Q.151 Chain D: S.160, G.161, S.163 Ligand excluded by PLIP SO4.17: 3 residues within 4Å: Chain D: S.69, G.70 Chain E: R.103 Ligand excluded by PLIP SO4.18: 3 residues within 4Å: Chain E: G.82, T.83, R.84 Ligand excluded by PLIP SO4.19: 2 residues within 4Å: Chain E: S.20, S.151 Ligand excluded by PLIP SO4.20: 3 residues within 4Å: Chain F: G.82, T.83, R.84 Ligand excluded by PLIP SO4.21: 6 residues within 4Å: Chain E: T.169, Q.170, R.172 Chain F: T.169, Q.170, R.172 Ligand excluded by PLIP SO4.22: 2 residues within 4Å: Chain F: L.16, R.18 Ligand excluded by PLIP SO4.23: 2 residues within 4Å: Chain F: S.20, S.151 Ligand excluded by PLIP SO4.24: 3 residues within 4Å: Chain F: M.106, R.107, S.108 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Pennington, L.F. et al., Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun (2016)

Release Date

2016-06-01

Peptides

Epididymis luminal protein 214: AC
Uncharacterized protein: BD
Ig epsilon chain C region: EF

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
H

C
A

B
L

D
B

E
G

F
I

Epididymis luminal protein 214

Uncharacterized protein

Ig epsilon chain C region

Related Entries With Identical Sequence